Trastuzumab is a humanized monoclonal antibody approved by the Food and Drug Administration (FDA) and used as a standard for the treatment of patients with HER-2-positive BC, as it decreases the risk of relapse (50%) and death (33%), increasing the overall survival of patients by 23–35% [16,17]. The gene discussed is ERBB2; the disease is breast cancer.